PBM
AARD

Propel Bio Management’s Aardvark Therapeutics AARD Stock Holding History

Propel Bio Management’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-46,408
Closed -$609K – 42
2025
Q4 		$609K Buy
+46,408
New +$579K 0.52% 18

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Propel Bio Management's AARD Position: Q1 2026 in Review

Propel Bio Management sold out of Aardvark Therapeutics (AARD) in Q1 2026, closing a stake of 46,408 shares — an estimated $609K sold.

Propel Bio Management first reported a position in AARD in Q4 2025 and held it in 1 quarter. The position peaked at $609K in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Propel Bio Management reported no remaining Aardvark Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Propel Bio Management sold 46,408 Aardvark Therapeutics shares in Q1 2026, an estimated $609K.
  • Propel Bio Management first reported a position in Aardvark Therapeutics in Q4 2025 and held it in 1 quarter.
  • Propel Bio Management's Aardvark Therapeutics position peaked at $609K in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Propel Bio Management's 13F filing for Q1 2026, filed 14 May 2026.